Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron‐overloaded patients with <b>β</b>‐thalassaemia: the ESCALATOR study

Abstract

The results of the ESCALATOR study in primarily heavily iron-overloaded patients confirm previous observations in patients with beta-thalassaemia, highlighting the importance of timely deferasirox dose adjustments based on serum ferritin levels and transfusional iron intake to ensure patients achieve their therapeutic goal of maintenance or reduction in iron burden.